Baotou Dongbao Bio-Tech Co.,Ltd cancelled the acquisition of an additional 60% stake in Inner Mongolia Dongbao Datian Biotechnology Co., Ltd. from Inner Mongolia Dongbao Trade Co., Ltd., Wang Fuhua and Chen Xidong.
April 07, 2021
Share
Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) agreed to acquire an additional 60% stake in Inner Mongolia Dongbao Datian Biotechnology Co., Ltd. from Inner Mongolia Dongbao Trade Co., Ltd., Wang Fuhua and Chen Xidong on April 8, 2020. As on December 31, 2019, Inner Mongolia Dongbao Datian Biotechnology reported total assets of CNY 5.5238 million, Net assets of CNY 2.5837 million, operating revenue of CNY 0.2715 million, operating loss of CNY 1.3618 million and net loss of CNY 1.0461 million. There is no need for approval from the shareholders’ meeting of the Baotou Dongbao. Transaction was approved by Board of Baotou Dongbao Bio-Tech.
Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) cancelled the acquisition of an additional 60% stake in Inner Mongolia Dongbao Datian Biotechnology Co., Ltd. from Inner Mongolia Dongbao Trade Co., Ltd., Wang Fuhua and Chen Xidong on April 8, 2021.
Baotou Dongbao Bio-Tech Co., Ltd is principally engaged in the research, development, manufacture and distribution of gelatin series products and low molecular mass collagen. The Company primarily provides gelatin, which is used in the manufacture of empty capsules and food additives; calcium hydrophosphate, which is used in feed additives, as well as collagen series products, which are used in foods, cosmetics, health care products. The Company distributes its products in both domestic and overseas markets, with domestic markets as its major markets.
Baotou Dongbao Bio-Tech Co.,Ltd cancelled the acquisition of an additional 60% stake in Inner Mongolia Dongbao Datian Biotechnology Co., Ltd. from Inner Mongolia Dongbao Trade Co., Ltd., Wang Fuhua and Chen Xidong.
BAOTOU DONGBAO BIO-TECH CO.,LTD 
